Monopar Therapeutics director Kim Tsuchimoto sells $455,566 in shares
Director Kim Tsuchimoto of Monopar Therapeutics (NASDAQ:MNPR) divested 4,090 shares of the company's common stock on August 26, 2026. The transaction, conducted under a pre-established Rule 10b5-1 trading plan, occurred at prices ranging from $108.07 to $114.34 per share, resulting in a total sale value of $455,566. This comes as Monopar's shares are trading near their 52-week high of $124.82, following a 228% increase over the past year.
Despite this recent sale, Tsuchimoto had previously exercised options to acquire 4,090 shares on the same day, with prices ranging from $14.00 to $30.00. Currently, Tsuchimoto holds no direct ownership of Monopar Therapeutics common stock, although the Kim R. Tsuchimoto Trust indirectly owns 11,486 shares. Monopar Therapeutics is in the process of submitting its New Drug Application (NDA) for ALXN1840, a treatment for Wilson disease.
Recent analyst reports have raised the stock's price target, with H.C. Wainwright increasing it to $125 and BTIG to $133, while Cantor Fitzgerald maintained a neutral stance with a $119 target, citing the stock as fairly valued.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
